



ABN 53 075 582 740

ASX ANNOUNCEMENT

18 November 2021

Bionomics Receives ASX Waiver from LR 10.13.5

Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company, refers to the Notice of Meeting for its Annual General Meeting to be held at 9:30am (ACDT) on Thursday, 2 December 2021, which was dispatched to shareholders on 1 November 2021 (**Notice of AGM**).

As noted in the Notice of AGM, the Company is proposing to undertake an initial public offering (**IPO**) in the United States and obtain a listing on the Nasdaq Stock Market.

Resolutions 9 and 10 of the Notice of AGM seek approval from shareholders pursuant to ASX Listing Rule 10.11 for two of the Company's substantial shareholders, Apeiron Investment Group Limited (**Apeiron**) and BVF Partners LP (and associated funds) (**BVF**), to participate in the IPO and apply for new fully paid ordinary shares in the Company (**New Shares**) (represented by American Depositary Shares (**ADS**)).

ASX Listing Rule 10.13.5 requires the Company to issue the New Shares to Apeiron and BVF no later than one month after the date of the AGM.

The Company is pleased to announce that it has been granted a waiver from ASX from the application of ASX Listing Rule 10.13.5 to the extent necessary to permit (and subject to shareholders approving Resolutions 9 and 10 (as applicable)) any Shares to be issued to Apeiron and BVF later than one month after the date of the AGM, on the following conditions:

1. any Shares issued to BVF and Apeiron under the IPO are issued at the same time as Shares are issued to unrelated holders participating in the IPO, and in any event no later than three months after the date of the AGM; and
2. the terms of this waiver are immediately released to the market.

Released on authority of the Company Secretary.

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400

CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB: BNOEF) is a clinical-stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates for patients affected by central nervous system (CNS) disorders. Bionomics' lead drug candidate BNC210 is a negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor. BNC210 oral tablet formulation is currently being

evaluated in a Phase 2b trial for the treatment of Post-Traumatic Stress Disorder (PTSD) for which it was granted Fast Track designation by the FDA. BNC210 is also being evaluated as an acute treatment in Social Anxiety Disorder (SAD) patients and is expected to enter a Phase 2 trial. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences, to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4- Methylenedioxymethamphetamine (MDMA) derivative EMP-01 for the treatment of PTSD. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

www.bionomics.com.au